Pricing strategies of originator and generic medicines following patent expiry in Belgium

Journal of Generic Medicines

Volumn 5, Issue 3, 2008, Pages 175-187

  Adriaen, Michael ^a   De Witte, Kristof ^a   Simoens, Steven ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ANTITUSSIVE AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; CAPTOPRIL; CARDIOVASCULAR AGENT; CEFADROXIL; CIMETIDINE; GASTROINTESTINAL AGENT; GENERIC DRUG; LAXATIVE; LORAZEPAM; MEBEVERINE; MUCOLYTIC AGENT; NAPROXEN; NEUROLEPTIC AGENT; OXAZEPAM; OXYBUTYNIN; SOTALOL; UNINDEXED DRUG; VASODILATOR AGENT;

ARTICLE; BELGIUM; COMPETITION; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; EXPIRATION DATE; PATENT; PREDICTION; PRESCRIPTION; PROSPECTIVE PRICING; REGRESSION ANALYSIS;

EID: 42449148192     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2008.8     Document Type: Article

References (14)

1. Grabowski, H. & Vernon, J. (1992). Brand loyalty; entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ 35, 331-350.
2. Frank, R. G. & Salkever, D. S. (1997). Generic entry and the pricing of pharmaceuticals. J Econ Manage Strategy 6, 75-90.
3. Caves, R. E., Whinston, M. D. & Hurwitz, M. A. (1991). Patent expiry and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity. Microeconomics 1991, 1-48.
4. Dalen, D. M., Strøm, S. & Haabeth, T. (2006). Price regulation and generic competition in the pharmaceutical market. Eur J Health Econ 7, 208-214.
5. Magazzini, L., Pammolli, F. & Riccaboni, M. (2004). Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur J Health Econ 5, 175-182.
6. Danzon, P. M. & Chao, L. W. (2000). Cross-national price differences for pharmaceuticals: How large, and why. J Health Econ 19, 159-195.
7. Simoens, S. & De Coster, S. (2006). Sustaining generic medicines markets in Europe. J Generic Med 3, 257-268.
8. Schulz, A. (2004). Evolving dynamics of US and European generics markets. J Generic Med 2, 23-32.
9. de Joncheere, K., Rietveld, A. H. & Huttin, C. (2002). Experiences with generics. Int J Risk Safety Med 15, 101-109.
10. King, D. R. & Kanavos, P. (2002). Encouraging the use of generic medicines: Implications for transition economies. Croat Med J 43, 462-469.
11. Simoens, S. (2007). International comparison of generic medicine prices. Curr Med Res Opin 23, 2647-2654.
12. Belgian Association of Generic Medicine Manufacturers (2007): http://www.febelgen.be, Belgian Association of Generic Medicine Manufacturers, accessed 21st November, 2007.
13. Simoens, S., Verhaegen, J., Laekeman, G. & Peetermans, W. E. (2005). Treating respiratory tract infections in ambulatory care in Belgium: Fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 26, 62-68.
14. General Association of the Medicines Industry (2007): http://www.pharma.be, General Association of the Medicines Industry, accessed 20th November, 2007.